Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Evidence of 177Lu-PSMA-617 use on or after March 23, 2022
Date of initiation of 177Lu-PSMA-617 available in the data
Age ≥18 years at index
You may not be if
None
Clareo Health | A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
